Savara (SVRA) Change in Accured Expenses (2010 - 2026)
Savara (SVRA) reported Change in Accured Expenses of -$4.6 million for Q1 2026, down 47.24% year-over-year from -$8.8 million in Q1 2025, and down 227.09% quarter-over-quarter from $3.6 million in Q4 2025.
Savara (SVRA) Change in Accured Expenses (2010 - 2026) Analysis & Trends
Savara (SVRA) has 17 years of Change in Accured Expenses data on file, last reported at -$4.6 million in Q1 2026.
- Change in Accured Expenses for Q1 2026 came in at -$4.6 million, down 47.24% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.3 million (up 82.06% YoY), and the FY2025 annual result was $4.8 million, up 14.4% from the prior year.
- Change in Accured Expenses eased to -$4.6 million in Q1 2026 per SVRA's latest filing, from $3.6 million in the prior quarter.
- Over five years, Change in Accured Expenses peaked at $3.6 million in Q4 2025 and troughed at -$4.6 million in Q1 2026.
- A 5-year average of $505529.4 and a median of $1.2 million in 2025 frame the typical range for Change in Accured Expenses.
- The sharpest annual moves came in 2023 and 2025: Change in Accured Expenses soared 6075.0% in 2023, then plunged 308.83% in 2025.
- A 5-year view of Change in Accured Expenses shows it stood at $445000.0 in 2022, then surged by 230.34% to $1.5 million in 2023, then soared by 53.74% to $2.3 million in 2024, then soared by 61.37% to $3.6 million in 2025, then tumbled by 227.09% to -$4.6 million in 2026.
- Business Quant data shows SVRA's Change in Accured Expenses at -$4.6 million in Q1 2026, $3.6 million in Q4 2025, and $3.1 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 931,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 70.50 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Savara | 1.39 Bn | 1.39 Bn | - | -4.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.64 Mn |
| Mar 31, 2026 | -4.64 Mn |
| Dec 31, 2025 | 3.65 Mn |
| Dec 31, 2025 | 3.65 Mn |
| Sep 30, 2025 | 3.12 Mn |
| Sep 30, 2025 | 3.12 Mn |
| Jun 30, 2025 | 1.19 Mn |
| Jun 30, 2025 | 1.19 Mn |
| Mar 31, 2025 | -3.15 Mn |
| Mar 31, 2025 | -3.15 Mn |
| Dec 31, 2024 | 2.26 Mn |
| Dec 31, 2024 | 2.26 Mn |
| Sep 30, 2024 | 1.38 Mn |
| Sep 30, 2024 | 1.38 Mn |
| Jun 30, 2024 | 1.34 Mn |
| Jun 30, 2024 | 1.34 Mn |
| Mar 31, 2024 | -770,000.00 |
| Mar 31, 2024 | -770,000.00 |
| Dec 31, 2023 | 1.47 Mn |
| Dec 31, 2023 | 1.47 Mn |